Sign inJoin waitlistJoin the waitlist

ER

Elyssa Rubin

Director, Bone and Soft Tissue Tumor Program, CHOC Hyundai Cancer Institute · University of California

Credentials: · ·

History

University of California
Present

Pediatric Hematology and Oncology at CHOC Hospital
2005–2006
Pediatrics
Kaiser Permanente Los Angeles Medical Center
2002–2005
Sackler School of Medicine, NY State/American Branch, Tel Aviv, Israel
1998–2002

Research

Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma
Molecular Cancer Therapeutics · 2010 · First of 6 authors · 115 citations
Induction of the early growth response (Egr) family of transcription factors during thymic selection
The Journal of Experimental Medicine · 1997 · 112 citations
Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience
Haemophilia · 2007 · 83 citations

Bang Hoang
4 papers
DR
Damon Reed
3 papers
Diane Nugent
2 papers
Jessica Davis
2 papers
Katherine Janeway
2 papers
Odion Binitie
2 papers
PG
Patrick Grohar
2 papers
Steven DuBois
2 papers
TD
Tuan Dao
2 papers
Ajay Gupta
1 paper
Alyaa Al-Ibraheemi
1 paper
Amit Soni
1 paper

Clinical trials

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031